Show simple item record

dc.contributor.authorMunz, Christian
dc.contributor.authorMoormann, Ann M.
dc.date2022-08-11T08:10:40.000
dc.date.accessioned2022-08-23T17:15:54Z
dc.date.available2022-08-23T17:15:54Z
dc.date.issued2008-11-11
dc.date.submitted2010-06-08
dc.identifier.citationSemin Cancer Biol. 2008 Dec;18(6):381-7. Epub 2008 Oct 19. <a href="http://dx.doi.org/10.1016/j.semcancer.2008.10.002">Link to article on publisher's site</a>
dc.identifier.issn1044-579X (Linking)
dc.identifier.doi10.1016/j.semcancer.2008.10.002
dc.identifier.pmid18996483
dc.identifier.urihttp://hdl.handle.net/20.500.14038/47273
dc.description.abstractPersistent Epstein-Barr virus (EBV) infection remains asymptomatic in the majority of virus carriers, despite the potent growth transforming potential of this virus. The increased frequency of EBV associated B cell lymphomas in immune compromised individuals suggests that tumor-free chronic infection with this virus is in part due to immune control. Here we discuss the evidence that loss of selective components of EBV specific immunity might contribute to EBV associated malignancies, like nasopharyngeal carcinoma, Burkitt's and Hodgkin's lymphoma, in otherwise immune competent patients. Furthermore, we discuss how current vaccine approaches against EBV might be able to target these selective deficiencies.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=18996483&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1016/j.semcancer.2008.10.002
dc.subjectAntigens, Viral
dc.subjectCD4-Positive T-Lymphocytes
dc.subjectCD8-Positive T-Lymphocytes
dc.subjectCancer Vaccines
dc.subjectEpstein-Barr Virus Infections
dc.subjectHIV Infections
dc.subjectHerpesvirus 4, Human
dc.subjectHumans
dc.subjectMalaria, Falciparum
dc.subjectNeoplasms
dc.subjectTumor Escape
dc.subjectVirus Activation
dc.subjectVirus Latency
dc.subjectBiostatistics
dc.subjectEpidemiology
dc.subjectHealth Services Research
dc.subjectImmunology and Infectious Disease
dc.subjectPediatrics
dc.titleImmune escape by Epstein-Barr virus associated malignancies
dc.typeJournal Article
dc.source.journaltitleSeminars in cancer biology
dc.source.volume18
dc.source.issue6
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/qhs_pp/413
dc.identifier.contextkey1347944
html.description.abstract<p>Persistent Epstein-Barr virus (EBV) infection remains asymptomatic in the majority of virus carriers, despite the potent growth transforming potential of this virus. The increased frequency of EBV associated B cell lymphomas in immune compromised individuals suggests that tumor-free chronic infection with this virus is in part due to immune control. Here we discuss the evidence that loss of selective components of EBV specific immunity might contribute to EBV associated malignancies, like nasopharyngeal carcinoma, Burkitt's and Hodgkin's lymphoma, in otherwise immune competent patients. Furthermore, we discuss how current vaccine approaches against EBV might be able to target these selective deficiencies.</p>
dc.identifier.submissionpathqhs_pp/413
dc.contributor.departmentDepartment of Pediatrics
dc.contributor.departmentDepartment of Quantitative Health Sciences
dc.source.pages381-7


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record